Avacta Group plc (LSE:AVCT) said Mats Blom has been appointed to its Board of Directors and will serve as Chair of the Audit Committee.
Blom succeeds Paul Fry, who is due to step down from the board at the end of September.
The company said Blom has experience as a chief financial officer and board member across European and US life sciences companies.
Appointment Comes as Clinical Pipeline Advances
The board change comes as Avacta Therapeutics continues development of its oncology pipeline and its proprietary pre|CISION platform.
The platform uses fibroblast activation protein, or FAP, to activate therapeutic payloads within the tumour microenvironment. According to the company, the approach is designed to concentrate cancer treatments in tumours while reducing systemic exposure and toxicity.
Avacta’s lead clinical programme is faridoxorubicin, also known as AVA6000, a FAP-enabled version of the chemotherapy drug doxorubicin.
The company has reported preliminary activity with AVA6000 in doxorubicin-sensitive tumour types, including salivary gland cancer and soft tissue sarcoma.
Avacta Focuses on Oncology Development
Avacta Therapeutics is a clinical-stage biopharmaceutical business within Avacta Group focused on oncology.
The company is developing its pre|CISION technology as a tumour-activated payload delivery platform, with AVA6000 representing its lead clinical programme.
Leave a Reply